Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia ® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Study Indicates That Prolia Led to Greater Gains in Bone Mineral Density at 12 Months Compared With Risedronate in Patients Receiving Glucocorticoid Therapy
THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment with Proli...
Source: Amgen News Release - September 17, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis
Real-World and Clinical Data Focus on Long-Term Efficacy and Safety of Prolia® (Denosumab), Provide Insights on Therapy Compliance in Patients With Postmenopausal Osteoporosis
THOUSAND OAKS, Calif., Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. 16-19,...
Source: Amgen News Release - September 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Xgeva (Denosumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 30, 2016 Category: Drugs & Pharmacology Source Type: news
Prolia (Denosumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 30, 2016 Category: Drugs & Pharmacology Source Type: news
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia ® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Study Indicates That Prolia Led to Greater Gains in Bone Mineral Density at 12 Months Compared With Risedronate in Patients Receiving Glucocorticoid Therapy
THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment with Proli...
Source: Amgen News Release - August 29, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Reports Second Quarter 2016 Financial Results
THOUSAND OAKS, Calif., July 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include:
Revenues increased 6 percent versus the second quarter of 2015 to $5.7 billion.
Product sales grew 5 percent driven by Enbrel® (etanercept), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab).
GAAP earnings per share (EPS) increased 15 percent to $2.47 driven by higher revenues and higher operating margins.
GAAP operating income increased 15 percent to $2,380 million and GAAP operating margin improved by 3.8 percentage...
Source: Amgen News Release - July 27, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Medical News Today: Breast cancer: Existing drug shows promise for prevention in high-risk women
An existing drug called denosumab has shown promise for the delay or prevention of breast cancer among women with a BRCA1 mutation. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2016 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Breast cancer cell growth halted by osteoporosis drug, study shows
A trial in mice has shown that the drug denosumab could become a preventative breast cancer treatment for women with BRCA1 gene mutationsWomen who have a high risk of breast cancer may benefit from a drug that is already prescribed to treat bone loss in old age, according to scientists in Australia.Researchers found that the osteoporosis drug, denosumab, can halt the growth of cells which give rise to breast tumours in women whose risk of the disease is greater because of mutations in a gene called BRCA1. Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 20, 2016 Category: Science Authors: Ian Sample Science editor Tags: Genetics Science Breast cancer Ovarian cancer Health Society Medical research Biology Source Type: news
Scientists reveal drug that prevents Angelina Jolie breast cancer gene could be step closer
Denosumab may have potential to prevent breast cancer from developing in women with BRCA1 gene, scientists from The Walter and Eliza Hall Institute, Australia found. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2016 Category: Consumer Health News Source Type: news
Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
First Quarter 2016 GAAP EPS Were $2.50
2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively
THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include:
Total revenues increased 10 percent versus the first quarter of 2015 to $5,527 million, with 7 percent product sales growth driven by Enbrel® (etanercept), Prolia® (denosumab), Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), Kyprolis® (carfilzomib) and XGEVA® (denosumab).
Adjusted EPS grew 1...
Source: Amgen News Release - April 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Combo Therapy vs Monotherapy for Postmenopausal OsteoporosisCombo Therapy vs Monotherapy for Postmenopausal Osteoporosis
The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Not to Diss Denosumab, but More Data Needed in Breast CancerNot to Diss Denosumab, but More Data Needed in Breast Cancer
Is it time to jump on the bisphosphonate bandwagon? Drs Kathy Miller and George Sledge review the adjuvant use in breast cancer and discuss new data on denosumab to make sense of all the controversy. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
2015 GAAP EPS Were $9.06
2016 Total Revenues and Adjusted EPS Guidance Increased to $22.0-$22.5 Billion and $10.60-$11.00, Respectively
THOUSAND OAKS, Calif., Jan. 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2015. Key results include:
For the fourth quarter, total revenues increased 4 percent to $5,536 million, with 3 percent product sales growth driven by Enbrel® (etanercept), Sensipar® (cinacalcet), Prolia® (denosumab), Kyprolis® (carfilzomib) and XGEVA® (denosumab). Adjusted operating income grew 16 percent to $2,366 million and...
Source: Amgen News Release - January 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
